[{"abstract": "Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion.", "web_url": "https://dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/", "snippet": "Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion.", "lead_paragraph": "Updated, 8:18 p.m. | The Swiss pharmaceutical giant Novartis and its British rival GlaxoSmithKline announced on Tuesday that they would swap more than $20 billion in assets as they seek to sharpen the focus of their businesses.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Novartis and Glaxo Agree to Trade $20 Billion in Assets", "kicker": "DealBook", "content_kicker": null, "print_headline": "Novartis and Glaxo Agree to Trade $20 Billion in Assets", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Botox (Drug)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Cancer", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Vaccination and Immunization", "rank": 4, "major": "N"}, {"name": "persons", "value": "Ackman, William A", "rank": 5, "major": "N"}, {"name": "persons", "value": "Jimenez, Joseph", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Eli Lilly and Company", "rank": 8, "major": "N"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 10, "major": "N"}, {"name": "organizations", "value": "Pershing Square Capital Management", "rank": 11, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 12, "major": "N"}], "pub_date": "2014-04-22T06:18:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray and David Jolly", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "David", "middlename": null, "lastname": "Jolly", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f", "word_count": 734, "uri": "nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f"}, {"abstract": "William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business.", "web_url": "https://dealbook.nytimes.com/2014/04/22/morning-agenda-ackmans-botox-ambitions/", "snippet": "William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business.", "lead_paragraph": "William A. Ackman, one of the brashest men on Wall Street, has come up with perhaps the boldest move yet for an activist: He has teamed up with the health care company Valeant to bid roughly $50 billion for Allergan, the maker of Botox, David Gelles, Michael J. de la Merced and Alexandra Stevenson write in DealBook. The offer by Valeant is expected to be announced Tuesday morning.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Ackman\u2019s Botox Ambitions", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-04-22T12:11:47+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2", "word_count": 1946, "uri": "nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2"}]